Sage’s phase 2 Alzheimer’s drug shows signs of cognitive improvement—but there’s a catchnews2022-04-01T13:33:05+00:00April 1st, 2022|FierceBiotech|
With 2023 launch in sight, Pharming shares pivotal data on ex-Novartis rare disease drugnews2022-04-01T12:03:30+00:00April 1st, 2022|FierceBiotech|
Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autismnews2022-04-01T10:49:48+00:00April 1st, 2022|FierceBiotech|
Layoff surge hits 3 more biotech companiesnews2022-03-31T22:08:16+00:00March 31st, 2022|FierceBiotech|
Fierce Biotech Layoff Tracker: Novartis, bluebird add to pile of 30-plus biotechs laying off staffnews2022-03-31T20:21:36+00:00March 31st, 2022|FierceBiotech|
Fierce Biotech Layoff Tracker: Kaleido closes up shop, Akebia cuts 42% of workforcenews2022-03-31T20:21:36+00:00March 31st, 2022|FierceBiotech|
Fierce Biotech Layoff Tracker: ProQR ousts 30% of staff after phase 2/3 setback, cuts across medtechnews2022-03-31T20:21:36+00:00March 31st, 2022|FierceBiotech|
Fierce Biotech Layoff Tracker: Layoffs hit small biotechs Finch, Imaranews2022-03-31T20:21:36+00:00March 31st, 2022|FierceBiotech|
Fierce Biotech Layoff Tracker: Judgement day for Nektar; SolidBio makes cutsnews2022-03-31T20:21:36+00:00March 31st, 2022|FierceBiotech|
Fierce Biotech Layoff Tracker: Spero cuts workforce after tough FDA call, Genocea crumblesnews2022-03-31T20:21:36+00:00March 31st, 2022|FierceBiotech|
